The triad treatment can improve the treatment effect for the chronic hepatitis C.
三联治疗能提高对慢性丙型肝炎的治疗效果。
The natural course of chronic hepatitis C varies considerably from one person to another.
在自然慢性丙型肝炎有很大的差别从一个人到另一个。
They were also observed in sera from patients with cryptogenic cirrhosis or chronic hepatitis c.
这些转录体在某些隐源性肝硬变和丙型肝炎患者血清中也存在。
An estimated 2.7 million Americans have chronic hepatitis c, and about 80% of them have no signs or symptoms.
大约有270万的美国人患有C型肝炎，其中的80%的没有迹象和症状。
This article introduces Professor Zhang Yunpeng's clinical experience in the treatment of chronic hepatitis c.
介绍张云鹏教授治疗慢性丙型肝炎的临床经验。
Objective To explore the changes of serum motilin(MTL) and gastrin(GAS) levels in patients with chronic hepatitis C.
目的：探讨了血清胃动素（MTL）、胃泌素（G AS）水平在慢性丙型肝炎患者中的变化及意义。
To compare predictive superiority among the parameters and search for reliable predictors of outcome in chronic hepatitis c.
比较各参数评价慢性C型肝炎预后预见优势，寻找慢性C型肝炎更可靠的预后评价因子。
Patients with chronic hepatitis C that has been resolved through therapy or immune response may still be able to infect others with the virus.
慢性病型肝炎患者通过治疗或因免疫应答作用使其肝炎看似解决后，可能仍然能够将该病毒传染给他人。
It is suggested that the cell immunity disorder caused by abnormality in T-lymphocyte subpopulation may be an important etiological factor of chronic hepatitis c.
认为T淋巴细胞亚群异常所致的细胞免疫紊乱可能是慢性丙型肝炎发病的重要原因。
ConclusionThe autoimmune manifestations are existed commonly in patients with chronic hepatitis C. The positive rate of autoantibody is correlated with age and cirrhosis.
结论慢性丙型肝炎患者中普遍存在自身免疫现象，自身抗体的检出率与患者的年龄和肝硬化发生率明显相关。
Some examples about the syndrome differentiation standardization of chronic hepatitis c, subclinical hepatic encephalopathy and hepatic hypochondriac pain were presented.
并以慢性丙型肝炎中医证型规范化研究，亚临床肝性脑病中医药诊治的研究，慢性肝病胁痛外治法的研究等实例说明之。
To study the expression of FAS antigens in peripheral blood mononuclear cells(PBMC) and liver tissues of patients with chronic hepatitis C (CHC) and the relationship between them.
观察慢性丙型肝炎（CHC）患者肝组织及外周血单核细胞（PBMC）FAS抗原表达对CHC病情的影响，进而探讨FAS系统与CHC 的关系及临床意义。
Background & Aims: Broadly reactive neutralizing antibodies (nAbs) and multispecific T-cell responses are generated during chronic hepatitis C virus (HCV) infection and yet fail to clear the virus.
背景和目的：慢性HCV感染过程中能够产生广泛的中和性抗体（nAbs）和多特异性的T细胞反应，但仍然不能够清除病毒。
Objective: The aim of this study was to evaluate the relationship between anti-interferon antibodies (anti-IFN Ab) and the therapeutic effect of interferon (IFN) in patients with chronic hepatitis C.
目的：探讨干扰素抗体与干扰素治疗慢性丙型肝炎临床疗效的关系。
Peripheral T-lymphocyte subsets of 48 HCV-RNA seropositive and 35 HCV-RNA seronegative chronic hepatitis -C patients were investigated arid 20 normal subjects were kept as control.
对48例血清HCV-RNA阳性和35例HCV-RNA阴性的慢性丙型肝炎（慢丙肝）患者外周血T淋巴细胞亚群进行观察，并与20例正常人对照。
Therefore, patients with chronic hepatitis B, hepatitis C should enhance the inspection, diagnosis and treatment.
因此，对于慢性乙肝病人，更应增强对丙肝的检查、诊治。
Conclusion: Anferon and ribavirin is safe and effective in the treatment of chronic hepatitis type c.
结论：安福隆联合利巴韦林治疗慢性丙型肝炎安全有效。
The breakthrough could cure other chronic viral infections, such as hepatitis B and C, and bacterial infections such as tuberculosis, he said.
这一突破可以治疗其他慢性病毒感染，如B和C型肝炎，肺结核等细菌感染，他说。
That patients with chronic hepatitis B treatment in contact with, as input, without anti-hepatitis C virus antibody testing of blood or blood products infected with hepatitis C, it is easy.
推测慢性乙肝病患在接触治疗时，由于输入未经抗丙肝病毒抗体检测的血液或血制品，就容易感染上丙肝。
We and others have pointed this out recently for several liver diseases, including chronic viral hepatitis B and c, alcoholic liver disease, and non-alcoholic fatty liver disease.
我们及其他研究者最近得出的这一结论适用于多种肝脏疾病，包括乙型慢性病毒性肝炎、丙型慢性病毒性肝炎、酒精性肝病和非酒精性脂肪肝。
We and others have pointed this out recently for several liver diseases, including chronic viral hepatitis B and c, alcoholic liver disease, and non-alcoholic fatty liver disease.
我们及其他研究者最近得出的这一结论适用于多种肝脏疾病，包括乙型慢性病毒性肝炎、丙型慢性病毒性肝炎、酒精性肝病和非酒精性脂肪肝。
应用推荐